Pyridostigmine

CHEMBL1115 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
181.2 g/mol
LogP
0.7
Phase
4

Pyridostigmine is a reversible acetylcholinesterase inhibitor of the carbamate class that prevents the hydrolysis of acetylcholine at cholinergic synapses, increasing the concentration and duration of action of acetylcholine at the neuromuscular junction and parasympathetic effector organs. It is primarily used for the symptomatic treatment of myasthenia gravis and has also been investigated as a pretreatment against nerve agent exposure.

आणविक भार

181.2100 g/mol

LogP

0.70

TPSA

33.40 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

क्रिया का तंत्र

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)C(=O)Oc1ccc[n+](C)c1

InChI

InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1

Molecular Formula

C9H13N2O2+

HBD / HBA

- / 2

घूर्णनीय बंधन

2

भारी परमाणु

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

Pyridostigmine is a reversible acetylcholinesterase inhibitor of the carbamate class that prevents the hydrolysis of acetylcholine at cholinergic synapses, increasing the concentration and duration of action of acetylcholine at the neuromuscular junction and parasympathetic effector organs. It is primarily used for the symptomatic treatment of myasthenia gravis and has also been investigated as a pretreatment against nerve agent exposure.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Pyridostigmine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1115. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4991. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.